| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
AVISE LUPUS
MessageSpecimens can be collected Monday-Thursday and before 1400EST on Fridays. Do NOT collect specimens on weekends or holidays.
A manual requisition will be sent from the Rheumatology office that needs to be sent with the specimens.
AVISE tests require special collection tubes kept in outpatient and processing.
A manual requisition will be sent from the Rheumatology office that needs to be sent with the specimens.
AVISE tests require special collection tubes kept in outpatient and processing.
Test Code
LAB01177
Alias/See Also
Exagen AVISE LUPUS
LAB01177
LAB01177
Includes
Anti-CCP IgG, ANA, Anti-dsDNA, EC4d, BC4d, Anti-Smith IgG, Anti-SS-B/La IgG, Anti-Scl-70 IgG, Anti-CENP IgG, Anti-Jo-1 IgG
If AVISE index is positive, AVISE SLE Prognostic will be added on if requested.
If AVISE index is positive, AVISE SLE Prognostic will be added on if requested.
Preferred Specimen
AVISE collection kit:
1 - Marble
1 - Large Lavendar/EDTA (10mL)
1 - Marble
1 - Large Lavendar/EDTA (10mL)
Transport Container
AVISE Shipping Kit
Transport Temperature
Refrigerated - Ice pack required when preparing AVISE Shipping kit.
Specimen Stability
Stability of 48 hours when Marble tube has been spun down.
Report Available
4-7 days
Clinical Significance
Antibodies to Cyclic Citrullinated Peptides (CCP) aid in the diagnosis of Rheumatoid Arthritis (RA). Anti-CCP antibodies are highly specific for RA.
ANA has high negative predictive value for ruling out SLE due to its high sensitivity for SLE. However, ANA is found in many autoimmune disorders and a significant proportion of apparently healthy individuals.
Anti-dsDNA antibodies provide high positive predictive value due to high specificity for SLE.
Cell-Bound Complement Activation Products (CB-CAPs) EC4d & BC4d are measures of classical complement activation. CB-CAPs are primarly associated with SLE with 66% of patients having one or both CB-CAPs elevated. EC4d significantly correlates with fluctuations in SLE disease activity.
Anti-Smith antibodies are highly specific, but comparatively low sensitvity marker for SLE.
Anti-SS-B/La antibodies are a low sensitivity but highly specific marker for Sjogren's Syndrome.
Up to 70% of scleroderma patients are positive for Anti-Scl-70. Anti-Scl70 is highly specific for diffuse cutaneous scleroderma and associates with interstitial lung disease.
Antibodies to (CENP) protein-B are found in 20-60% of patients with CREST syndrome, a limited form of scleroderma.
Anti-Jo1 is a marker to aid in diagnosis of PM/DM. Foun din about 25% of patients with PM/DM.
ANA has high negative predictive value for ruling out SLE due to its high sensitivity for SLE. However, ANA is found in many autoimmune disorders and a significant proportion of apparently healthy individuals.
Anti-dsDNA antibodies provide high positive predictive value due to high specificity for SLE.
Cell-Bound Complement Activation Products (CB-CAPs) EC4d & BC4d are measures of classical complement activation. CB-CAPs are primarly associated with SLE with 66% of patients having one or both CB-CAPs elevated. EC4d significantly correlates with fluctuations in SLE disease activity.
Anti-Smith antibodies are highly specific, but comparatively low sensitvity marker for SLE.
Anti-SS-B/La antibodies are a low sensitivity but highly specific marker for Sjogren's Syndrome.
Up to 70% of scleroderma patients are positive for Anti-Scl-70. Anti-Scl70 is highly specific for diffuse cutaneous scleroderma and associates with interstitial lung disease.
Antibodies to (CENP) protein-B are found in 20-60% of patients with CREST syndrome, a limited form of scleroderma.
Anti-Jo1 is a marker to aid in diagnosis of PM/DM. Foun din about 25% of patients with PM/DM.
Performing Laboratory
Exagen Inc.